Nectar Lifesciences to sell API business and formulations for Rs 1,270 crore

08 Jul 2025 Evaluate

Nectar Lifesciences has signed a definitive Business Transfer Agreement (BTA) for the sale of its core business division -- comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations -- to Ceph Lifesciences, for a consideration of Rs 1,270 crore, on a slump sale basis. Additionally, the company has entered into an Asset Purchase Agreement (APA) for the sale of its menthol business assets to Ceph Lifesciences for Rs 20 crore, marking a comprehensive restructuring move aligned with its future strategy.

This transaction forms a part of the company’s long-term strategy to streamline its operations, strengthen its financial position, and unlock value for shareholders. The proceeds from the sale will be used to repay existing debt, invest in new and emerging business areas, fund future corporate and growth initiatives.

Nectar Lifesciences has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Nectar Lifesciences Share Price

20.94 0.00 (0.00%)
05-Dec-2025 14:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1802.00
Dr. Reddys Lab 1275.00
Cipla 1518.00
Zydus Lifesciences 930.30
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×